Abstract: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.

Abstract: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.

Abstract: The invention relates to a method for producing water dispersible dry powders from hardly soluble compounds, whereby a dispersion is provided, containing the poorly soluble compound in a microdispersed form in a dispersion agent. The dispersion of the poorly soluble compound is concentrated by tangential-filtration and the dispersion agent is removed. The invention also relates to preparations based on said water dispersible dry powders.

Abstract: The invention concerns a method for producing solid galenic formulations which consists in: forming a processable paste comprising a) 50 to 99.4 wt. % of at least one non-thermoplastic carrier, b) 0.5 to 30 wt. % of at least an adjuvant selected among thermoplastic polymers, lipids, sugar alcohols and solubilizing agents, c) 0.1 to 49.5 wt. % of at least one active principle, at a temperature not less than the softening temperature of the adjuvant but rising to at least 70° C.; then in cooling the resulting paste. Said solid galenic formulations quickly disintegrate in an aqueous medium.

Abstract: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.

Abstract: The present invention relates to an apparatus for producing solid active ingredient-containing forms from an active ingredient-containing formulation which comprises at least one polymeric binder. The apparatus according to the invention has at least one extruder 1 for continuous plastication of the formulation and at least two injection units 2 which are provided separate from one another, each of which is connected to the extruder 1, and through which the formulation can be injected into at least one mold 3.

Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.

Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: A solid or semisolid, at least two-phase active ingredient-containing formulation in which there is multiparticulate incorporation of one of the two phases into a matrix of the other phase, and at least one of the phases contains at least one active ingredient, obtainable by introducing particles of one phase into the other phase in a plastic state, and shaping the material while still plastic.

Abstract: A process for producing solid dosage forms by a) producing a plastic mixture which comprises at least one active ingredient and at least one polymeric binder, and b) shaping the plastic mixture to the solid dosage forms in a molding calender with two counterrotating molding rolls, wherein one molding roll has at least one annular groove running along its periphery and the other molding roll has at least one ring, running along its periphery, of teeth extending radially outward and able to engage in the annular groove is described.

Abstract: A solid dosage form for application in the oral cavity, comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.

Abstract: The invention relates to stable solid dosage forms for peroral administration containing, in addition to an ubiquinone, at least one thermoplastically processible matrix-forming auxiliary agent.

Abstract: The invention relates to a process and an apparatus for producing solid dosage forms by molding plastic active ingredient-containing mixtures with use of a continuously operating molding tool with two parts which cooperate to mold the plastic mixture, with at least one part having a plurality of depressions to receive and mold the plastic mixture, wherein one part has at least two groups, which differ in volume and/or shape, of depressions. Dosage forms which differ in shape or size are obtained in one step.

Abstract: A process for producing solid dosage forms by forming a plastic mixture of at least one polymeric binder, at least one active ingredient and, where appropriate, conventional additives, and shaping the plastic mixture to the solid dosage forms using a mold, wherein an agent which modifies the surface properties is applied in finely divided form to the surface of the plastic, mixture during the shaping is described. The agent which modifies the surface properties is preferably a surfactant, a lipophilic compound, an antioxidant, a coloring agent or an agent with antistatic effect and/or lubricant effect.

Abstract: The present invention relates to mechanically stable pharmaceutical presentations for oral administration, comprising in addition to one or more active ingredients and at least one melt-processable matrix-forming excipient more than 10 and up to 40% by weight of a surface-active substance with an HLB of from 2 to 18, which is liquid at 20° C. or has a drop point in the range from 20 to 50° C.

Abstract: Solvent-free noncrystalline bioactive substances are prepared from the corresponding crystalline bioactive substances in an extruder by melting the substances in the extruder under reduced pressure and in the absence of auxiliaries, cooling and comminuting.

Abstract: Solid, elongate dosage forms (10) with a long axis (11) and with a length (L) which is defined by projection of the ends (12, 13) of the dosage form to the long axis, where a cross-sectional area (14, 15, 16) oriented perpendicular to the long axis (11) has an area which is variable along the long axis (11) and increases from a cross-sectional area (15) which is located between the ends (12, 13) and has a minimal area essentially continuously toward the two ends (12, 13) up to in each case a cross-sectional area (14 and 16 respectively) with a maximal area, wherein the distance of the maximal cross-sectional area (14) which is located near one end (12) from the maximal cross-sectional area (16) which is located near the other end (13) is, projected on the long axis (11), more than half the length (L) of the dosage form (10), are described.

Abstract: Lipids are used as aids in the production of solid drug forms by melt extrusion.